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Abstract
The incidence of melanoma is increasing over the years with a still poor prognosis and the lack of a cure able to
guarantee an adequate survival of patients. Although the new immuno-based coupled to target therapeutic strategy is
encouraging, the appearance of targeted/cross-resistance and/or side effects such as autoimmune disorders could
limit its clinical use. Alternative therapeutic strategies are therefore urgently needed to efficiently kill melanoma cells.
Ferroptosis induction and execution were evaluated in metastasis-derived wild-type and oncogenic BRAF melanoma
cells, and the process responsible for the resistance has been dissected at molecular level. Although efficiently induced
in all cells, in an oncogenic BRAF- and ER stress-independent way, most cells were resistant to ferroptosis execution. At
molecular level we found that: resistant cells efficiently activate NRF2 which in turn upregulates the early ferroptotic
marker CHAC1, in an ER stress-independent manner, and the aldo-keto reductases AKR1C1 ÷ 3 which degrades the 12/
15-LOX-generated lipid peroxides thus resulting in ferroptotic cell death resistance. However, inhibiting AKRs activity/
expression completely resensitizes resistant melanoma cells to ferroptosis execution. Finally, we found that the
ferroptotic susceptibility associated with the differentiation of melanoma cells cannot be applied to metastatic-derived
cells, due to the EMT-associated gene expression reprogramming process. However, we identified SCL7A11 as a
valuable marker to predict the susceptibility of metastatic melanoma cells to ferroptosis. Our results identify the use of
pro-ferroptotic drugs coupled to AKRs inhibitors as a new valuable strategy to efficiently kill human skin
melanoma cells.
Introduction
Cutaneous melanoma represents one of the most
aggressive and difficult to treat forms of human cancer,
with a worldwide incidence that has steadily increased
over the past 40 years1,2. Notoriously unresponsive to
conventional chemotherapy, the metastatic disease is
highly invasive and evolves with an extensive repertoire of
molecular defenses against immunological and cytotoxic
attacks3. Although linked to exposure to ultraviolet light,
both genotypic and phenotypic changes in melanocytes
predispose to transformation and melanomagenesis4,5.
Although several gene mutations have been observed in
this malignancy6, oncogenic mutations in the Ras/Raf
pathway are those most frequently associated with the
development of melanoma7. Indeed, up to 80% of all
melanomas harbor activating NRAS or BRAF muta-
tions8,9, with BRAFV600E representing more than 90% of
BRAF mutations, resulting in constitutive activation of the
signaling pathway, promoting melanoma proliferation and
resistance to apoptosis10. Since both NRAS/BRAF muta-
tions are frequently present in benign nevi, other factors
are required to drive melanomagenesis7,8. In fact, both
autophagy and ER stress, primarily pro-survival processes,
have accordingly been postulated as secondary events
contributing to melanoma development and, importantly,
playing a key role in chemoresistance11,12. Particularly,
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oncogenic BRAF drives a chronic ER stress status directly
controlling basal autophagy13,14, resulting in enhanced
chemoresistance of these cells13,15. In contrast, the phar-
macological alteration of autophagy has a positive effect
on the response of BRAF wild-type melanomas to treat-
ment14, indicating the high heterogeneity of this malig-
nancy with the ability to evolve with an extensive
repertoire of molecular defenses against pro-death
stimuli.
In the past decade, treatment options for metastatic
melanoma have significantly increased with the arrival of
BRAF inhibitors and BRAF/MEK combination therapy.
However, despite FDA-approved BRAF-targeted therapies
for advanced stage melanoma showed a great deal of
promise, development of rapid resistance limits their
success16–18. Therefore, the success of melanoma therapy
still remains one of the worst, compared to other malig-
nancies. Very recently, an immune-based therapeutic
approach has been developed, mainly using CTLA-4 and/
or PD-1 inhibitor. PD-1 inhibitors seem to be the most
promising as first-line therapy as they can produce high
response rates with long-term tumor remission, while
maintaining more tolerable side effect profiles19–22.
Combinations of targeted therapies and immune-based
therapies may show improved efficacy, but also carry an
increased risk of adverse effects, together with cross-
resistance23. Therefore, novel therapeutic strategies are
urgently needed.
Recently, an alternative iron-dependent cell death
pathway, named ferroptosis, has been identified24.
Although the precise molecular mechanisms regulating
this death pathway are still elusive and under deep
investigation, its induction was originally described rely-
ing on the inhibition of the cystine uptake by the cystine/
glutamate antiporter system (system XC−), located onto
the cell membrane24, resulting in the inhibition of glu-
tathione peroxidase 4 (Gpx4) and depletion of glu-
tathione, determining the imbalance of the reduced/
oxidized glutathione system, the main antioxidant cell
system, and induction of the ER stress pathway25.
Downstream, lipid peroxides generation represents a key
step mediating the execution of this death process26. In
this context, the downstream upregulation/activation of
specific members of the aldo-keto reductases (AKRs) gene
family (AKR1C1 ÷ 3) has been proposed as factors cata-
lyzing the conversion of aldehydes and ketones to their
corresponding alcohols, therefore possibly detoxifying the
highly dangerous reactive molecules lipid peroxides, thus
inhibiting the execution of ferroptosis24.
Here we show that ferroptosis is potentially inducible in
melanoma cell lines although its execution is inhibited in
most of them, due to the upregulation and activation of
downstream AKRs, through the main oxidative
stress-linked transcription factor NRF2. However, we
demonstrate that inhibiting the expression/activity of
these enzymes or blocking NRF2 action re-establish the
normal execution of ferroptosis.
Results
Erastin induces an ER stress-independent upregulation of
the early ferroptotic marker CHAC1 in melanoma cells
Although the precise molecular mechanisms of fer-
roptosis are still unknown and under deep investigation,
the upregulation of CHAC1 is widely accepted as an
early ferroptotic marker, also contributing to glu-
tathione degradation and ferroptosis execution24.
Therefore, we decided to evaluate the ability of the
typical inducer erastin (ERA) to stimulate the ferrop-
totic induction in melanoma cells. To this aim, we
exposed our panel of wild-type and oncogenic BRAF
human melanoma cell lines13 to ERA and CHAC1 gene
expression was evaluated by qRT-PCR. Data shown in
Fig. 1a indicate that the expression of CHAC1 is
promptly upregulated in all tested melanoma cells (2 h
post-ERA treatment). Moreover, enhanced CHAC1
expression levels are maintained even later, indicating
the progress of the ferroptotic process (Suppl. S1). Since
previous reports linked the expression of CHAC1 to ER
stress induction27 with the latter signaling pathway
potentially contributing to ferroptosis25, we evaluated
whether this was also the case with melanoma cells. To
explore this hypothesis, CHL-1, A375, C8161, and SK-
Mel 5 cells were treated or untreated 2 and 4 h with ERA
and the expression of the ER stress markers ATF4,
ATF6, XBP1 and CHOP/Gadd153 was evaluated by
qRT-PCR, using thapsigargin (TG) as positive control.
Surprisingly, our results indicate no significant upre-
gulation of any of the ER stress marker (Fig. 1b), indi-
cating that ER stress is not involved in ferroptosis
induction and CHAC1 upregulation is ER stress-
independent under pro-ferroptotic stimuli, at least in
melanoma cells. To further support these conclusions,
we also dissected out the activity of the ER stress PERK/
ATF4/CHOP signaling pathway, previously indicated to
be responsible for CHAC1 gene expression regulation28.
To this aim, CHL-1 cells were treated or untreated 2 h
with ERA or TG and the phosphorylation of PERK and
the downstream ERAD marker Herp29 were evaluated
by western blotting analysis30. Data reported in Fig. 1c
clearly show neither the activation of PERK (upper
panel), nor a significant upregulation of Herp (bottom
panel). We also inhibited the expression of ATF4 in
CHL-1 cells by transiently transfecting two siRNA oli-
gos specific for ATF4 (siATF4#5 and siATF4#9), using a
scrambled sequence (siCTRL) as a control (Fig. 1d, left
panel), and evaluated the expression of CHAC1 under
ERA treatment (2 h), by qRT-PCR. Results indicate the
ablation of ATF4 expression does not prevent the ERA-
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stimulated upregulation of CHAC1 (Fig. 1d, right panel).
Similar results were also obtained inhibiting the
expression of CHOP, in the same experimental condi-
tions (Suppl. S2). Collectively these results indicate that
erastin induces the early expression of the ferroptotic
marker CHAC1 in an ER stress-independent manner,
thus also indicating that the latter process is not evoked
during ferroptosis stimulation in melanoma cells.
Most melanoma cell lines are resistant to ferroptosis
execution, independently from BRAF oncogenic status
To verify the efficacy of ferroptosis induction resulting
in melanoma cell death completion, the cell viability of
our panel of melanoma cells was evaluated at 24 and 48 h
post-erastin treatment. Surprisingly, the data shown in
Fig. 1e (and Suppl. S3) indicate that most (five out of
seven) of melanoma cell lines are resistant to ferroptosis
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Fig. 1 Ferroptosis induction and execution in melanoma cells is ER stress- and oncogenic BRAF- independent. a The indicated melanoma cell
lines were treated 2 h with erastin (10 μM) and CHAC1 expression was evaluated by qRT-PCR. (The histograms represent the expression of
CHAC1 stimulated by erastin with respect to each control, which has been arbitrarily set on 1, in each individual cell line, dotted line). b The expression
level of the ER stress markers ATF4, ATF6, XBP1, and CHOP was evaluated in CHL-1, C8161, SK-Mel 5 and A375 cell lines treated or untreated with
erastin, at indicated time points, by qRT-PCR. Thapsigargin (10 μg/ml, 4 h) was used as positive control. c The activation of PERK and Herp
upregulation were evaluated in CHL-1 cells treated (2 h) or untreated, C, with erastin, E, or thapsigargin, T, by western blotting analysis. Tubulin was
used as loading control. d The expression of ATF4 was downregulated in CHL-1 cells by transient transfection of specific siRNA sequences (siATF4#5
and siATF4#9; a scrambled sequence was used as control, shCTRL) and ATF4 (left panel) or CHAC1 (right panel) mRNA levels were evaluated by qRT-
PCR, in cells treated or untreated 2 h with erastin (10 μM), as indicated. e The indicated melanoma cell lines were exposed 24 or 48 h to erastin
(10 μM) and cell viability was evaluated by measuring the percentage of FDA+/7AAD- cells, by flow cytometry. f C8161 cells were exposed to ERA
(10 μM) in presence or absence of 2-Mercaptoethanol (βME, 100μM) or Ferrostatin-1 (Fer-1, 10μM) and cell viability was evaluated 48 h post-
treatment, as reported in E. g A375 and SK-Mel 5 cells were treated 8 h with erastin (10 μM) in presence or absence of Vemurafenib (VER, 10 μM; 2 h
pre-treatment) and BRAF kinase activity was evaluated by measuring the phosphorylation levels of the protein target ERK1/2 (P-ERK1/2). Tubulin and
ERK1/2 were used as loading controls. h CHL-1, A375 or SK-Mel 5 cells were exposed to ERA (10 μM; 24 or 48 h) in presence or absence of
Vemurafenib (VER, 10 μM; 2 h pre-treatment) and cell viability was evaluated as in E. (Histograms represent mean ± s.d.; n= 3; ns= not significant,
compared to controls; *p < 0,05, compared to controls; w.b.; images are representative of three independent experiments).
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execution despite early CHAC1 upregulation (Fig. 1a). To
confirm that erastin was able to stimulate the ferroptotic
process in sensitive cell lines, C8161 cells were then
exposed to ERA in presence or absence of the ferroptotic
inhibitors Ferrostatin-124 or 2-Mercaptoethanol25 and cell
viability was evaluated. Results shown in Fig. 1f (and
Suppl. S3) demonstrate that ERA-induced cell death was
completely inhibited by Ferrostatin-1 or 2-Mercap-
toethanol, indicating that C8161 cells were dying through
ferroptosis. Importantly, data shown in Fig. 1e also indi-
cate that melanoma cell resistance to ferroptosis execu-
tion is potentially independent of BRAF mutational status,
since oncogenic BRAF cells were both sensitive (A2058
and C8161) or resistant (A375, SK-Mel 5) to ferroptosis
execution. To further exclude a role of BRAF mutations in
melanoma resistance to ferroptotic cell death, A375 and
SK-Mel 5 oncogenic BRAF melanoma cell lines were
treated with erastin in presence or absence of the specific
BRAF inhibitor Vemurafenib (VER, 10 μM; 2 h pre-
treatment), using the BRAFWT CHL-1 cell line as negative
control. Our results indicate that inhibiting the activity of
mutant BRAF (Fig. 1g) does not resensitize melanoma
cells to ferroptosis execution (Fig. 1h), at least as short-
term treatment.
Ferroptosis resistance is associated with downstream
AKR1C1 ÷ 3 upregulation
Cancer cells are characterized by deregulated pro-
liferation and evolve a wide repertoire of defense
mechanisms promoting cell survival and inhibiting cell
death, particularly active under adverse environmental
conditions such as anti-cancer treatments. Therefore, it is
not surprising that many melanoma cells can also be
resistant to ferroptosis. Understanding the molecular
mechanism(s) conferring resistance might therefore be
useful to identify new therapeutic targets. To this aim, we
took advantage of results from Stockwell work indicating
that AKRs are potentially downstream ferroptotic inhibi-
tors24. AKRs are a family of enzymes basically deputed to
the conversion of aldehydes or ketones into their corre-
sponding alcohols, thus inhibiting their cytotoxic poten-
tial. They are implicated in several biochemical pathways
and especially abundant in the liver31. Their anti-
ferroptotic role is thus potentially related to their detox-
ifying activity, resulting in the reduction of lipid per-
oxides, the key executioners of the ferroptotic cell death
process32. To explore whether this was the case in mela-
noma, we evaluated the mRNA levels of the three can-
didates AKR1C1, AKR1C2, and AKR1C3 in our cell lines,
upon erastin treatment. Therefore, resistant CHL-1 and
SK-Mel 5 were exposed 2 or 8 h to 10 μM ERA and
mRNA levels of the three enzymes were evaluated by
qRT-PCR. Results were then compared to those from the
sensitive C8161 and A2058 cell lines, obtained in the same
experimental conditions. Data indicate that the expression
of all three enzymes was promptly and significantly
upregulated in both resistant cell lines (CHL-1 and SK-
Mel 5) to as early as 2 h after treatment. In contrast, no
upregulation—but an interestingly slight but consistent
downregulation—was observed in the sensitive (C8161
and A2058) cell lines of any of the three enzymes (Fig. 2a).
These results were confirmed by western blotting analysis,
in which increased protein levels of AKR1C1 ÷ 3 were
evident in resistant A375 cells treated 16 h with erastin,
compared to control, while no upregulation was observed
in the sensitive C8161 (Suppl. S4). Collectively these data
indicate a potential role of AKRs upregulation in mela-
noma cell resistance to ferroptosis execution. Due to the
high heterogeneity of AKR1C1 ÷ 3 upregulation under
erastin treatment observed in resistant cells, we next
compared both basal and stimulated (2 h ERA) mRNA
levels of each individual AKR1Cs among resistant cell
lines CHL-1, SK-Mel 5, and A375. Interestingly, this
analysis revealed, with good approximation, an inversely
proportional relationship between basal (Fig. 2b, bottom
panel) and stimulated expression (Fig. 2b, upper panel), of
each of the three genes and among the three cell lines.
AKRs inhibition resensitize cells to ferroptosis execution
To verify the role of AKRs enzymatic activity in lipid
peroxide demolition in melanoma cells, resistant cell lines
were exposed 24 or 48 h to ERA, in presence or absence of
the AKR1C1 ÷ 3 pan inhibitor medroxyprogesterone33
(MPA; 10 μM), and cell viability was evaluated as reported
above. Data shown in Fig. 2c and supplementary S3 and
S5 clearly indicate that combined ERA+MPA treatment
consistently resensitize all resistant melanoma cell lines to
ferroptotic cell death, although with different kinetics.
Next, we individually inhibited the expression of each of
the three enzymes in both CHL-1 and SK-Mel 5 by
infecting cells with lentiviral particles carrying specific
shRNA targeting the three targets. A total of five shRNA
sequences were tested for each individual AKR and the
one conferring the best silencing efficiency was used in
the next experiments (shC1 to AKR1C1, shC2 to
AKR1C2, and shC3 to AKR1C3); a scrambled shRNA
sequence was used as control (shSc). The silencing effi-
ciency was confirmed 48 h post-infection by qRT-PCR
analysis (Suppl. S6), cells were then exposed 24 h to era-
stin and cell viability was evaluated by flow cytometry.
Data reported in Fig. 2d indicate that inhibiting the
expression of each individual enzyme results in enhanced
erastin-stimulated ferroptotic cell death in both cell lines.
To further confirm these results, A375 and A2058 cells
were treated with a second ferroptotic inducer, RLS3.
Thus, both cell lines were exposed to 2 μM RLS3 and both
AKR1C1 ÷ 3 and CHAC1 gene expression were evaluated
2 h post-treatment, by qRT-PCR. As expected, CHAC1
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expression was upregulated in both cell lines, thus con-
firming results reported in Fig. 1a, while AKR1C1 ÷ 3
mRNA levels were increased in A375 (Fig. 2e, left panel)
but not in A2058 cells (Fig. 2f, left panel). The same cell
lines were then exposed 24 h to RLS3 alone or in com-
bination with Ferrostatin-1 (both cell lines) or with MPA
or Deferoxamine (an iron chelator;24 A375 only), and cell
viability was evaluated by flow cytometry. Data reported
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in Fig. 2e and F (right panels) show that A2058 were
sensitive to RLS3 induced cell death, while A375 were
mostly resistant; moreover, RLS3 treatment induces a
ferroptotic cell death process in both cell lines since
ferrostatin-1 (A375 and A2058) or deferoxamine (A375)
completely protected both cell lines (Fig. 2e, f). Impor-
tantly, data reported in Fig. 2e, f also show a clear cor-
relation between cell resistance to pro-ferroptotic drug
and AKR1C1 ÷ 3 gene expression upregulation, thus fur-
ther sustaining previous conclusions. Finally, AKR1C3
was transiently over-expressed in A2058, by transient
transfection (Suppl. S7), and cell viability was evaluated
24 h post-erastin treatment, in presence or absence of
MPA (Fig. 2g). Data reported in Fig. 2g and Supplemen-
tary S7 clearly show that AKR1C3 overexpression confers
resistance of sensitive A2058 to erastin-induced ferrop-
totic cell death while MPA, inhibiting AKR1C3 enzymatic
activity, reverts the process.
Collectively these results show that AKR1C1 ÷ 3 gene
expression upregulation and enzymatic activity are
responsible for inhibited ferroptosis execution in resistant
melanoma cells and that the activity of each individual
enzyme seems to be equally required.
LOX-mediated lipid peroxides generation are essential for
ferroptosis execution
Our above results showing AKR1C1 ÷ 3 enzymatic
activity resulting in ferroptosis execution inhibition imply
that lipid peroxides production are crucial executioners of
the ferroptotic cell death program also in melanoma cells.
Indeed, although the detailed molecular mechanism(s)
driving the ferroptotic cell death process from induction
to execution is still unclear, the key role played by lipid
peroxides is, however, well consolidated although the link
between their generation and action is still not completely
known32,34. Interestingly, although their generation was
initially considered the result of intracellular iron accu-
mulation and consequent Fenton’s reactions35, it is now
evident that they can also be produced by intracellular
lipoxygenases enzymatic activity36. Therefore, to evaluate
the role and source of lipid peroxides in our system,
sensitive A2058 cells were exposed 16 h to erastin and
lipid peroxides generation was evaluated by measuring the
fluorescence of the specific probe BODIPY C11, by flow
cytometry. Results reported in Fig. 3a (left and middle
panels) show a huge generation of lipid peroxides under
erastin treatment (compare E with C columns, erastin and
control respectively), thus preceding the cell death
execution. Interestingly, while A375 and CHL-1 cells were
treated as the sensitive A2058, a consistently lower lipid
peroxides production was evidenced in both cell lines,
even at 24 h post-treatment (Fig. 3b, c, left and middle
panels), perfectly correlating with enhanced AKR1Cs
expression and resistance of these cell lines to erastin-
induced ferroptotic cell death (Figs. 2a and 1e, respec-
tively). In fact, the link between erastin-induced lipid
peroxides levels and ferroptosis execution is clearly shown
by the enhanced elevation of lipid peroxides in cells
exposed to ERA in presence of MPA, compared to ERA
alone (compare E+M with E columns in left panels of
Fig. 3a–c), resulting in cell death induction in both
resistant cell lines (Fig. 3b, c, right panels, compare E with
E+M columns). To determine the source of lipid per-
oxides generation, we exposed our sensitive A2058 cell
line to erastin in the presence or absence of the 12/15-
lipoxygenase (ALOX12 and ALOX15) inhibitor Baicalein
(BAI)37 and lipid peroxides generation and cell death were
evaluated. Data reported in Fig. 3a show that BAI com-
pletely prevented both lipid peroxides generation and
ferroptosis execution in A2058 exposed to ERA. Next, we
exposed the two resistant A375 and CHL-1 cells to erastin
in presence of MPA—to inhibit AKR1Cs activity and lipid
peroxides degradation—or Baicalein—to inhibit 12/15-
LOX—and lipid peroxides and cell viability were eval-
uated at 24 and 48 h, respectively. Data reported in Fig.
3b, c show that BAI completely inhibited both lipid per-
oxides generation and ferroptotic cell death induction, in
both cell lines in which the AKR1Cs activity was inhibited
by MPA (compare E+M with E+M+ B columns).
These results are also confirmed by data showing that BAI
completely abrogated the accumulation of lipid peroxides
in A375 cells exposed to RLS3, while Zileuton—a 5-
lipoxygenase inhibitor—did not (Suppl. S8). Collectively
these data indicate that lipid peroxides are key execu-
tioners of the ferroptotic program also in melanoma cells,
are generated by 12/15-lipoxygenase and degraded by
AKR1C1 ÷ 3.
NRF2 regulates AKR1C1 ÷ 3 expression upon ferroptosis
induction
Due to the key role played by AKRs in ferroptosis
resistance in melanoma cells, we investigated the mole-
cular mechanism(s) regulating their expression. To this
aim, we focused our attention on the canonical tran-
scription factor (TF) NRF2, representing a perfect link
between oxidative stress response38 and AKRs regula-
tion39. Since NRF2 is usually dysregulated in cancer40,
including melanoma41, we first evaluated the transcrip-
tional levels of this TF in our cell lines. As shown in Fig. 4a,
data confirm a heterogeneous expression of NRF2 in
melanoma cells. Next, we evaluated the potential activa-
tion of this TF upon ferroptosis induction. To explore this
hypothesis, resistant and sensitive cells were exposed to
ERA (4 h) or H2O2 (positive control), and mRNA levels of
NRF2 or its target HO1 were evaluated by qRT-PCR
(Fig. 4b, c and Suppl. S9A). Data indicated the upregula-
tion of NRF2 under ERA treatment, paralleled by
enhanced expression of its downstream gene target HO1
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(Fig. 4b right panel). To further confirm these results,
NRF2 protein levels were evaluated in the same cells
treated or untreated with erastin (4 h) in presence of
MG132 (2 h pre-treatment), to inhibit NRF2 proteasome-
mediated degradation. Western blotting analysis reported
in Fig. 4c and Supplementary S9B show enhanced protein
levels in cells co-treated with ERA and MG132 compared
to MG132 alone. Collectively these data indicate that
NRF2 is activated early during ferroptosis induction. Next,
to evaluate the potential contribution of NRF2 activation
in the ERA-stimulated AKR1C1 ÷ 3 upregulation, CHL-1
cells were treated or untreated with ERA (4 h) in presence
or absence of Brusatol42, an NRF2 inhibitor, and mRNA
levels of the three AKR1Cs were evaluated by qRT-PCR.
Results clearly indicate that inhibiting NRF2 activity
results in consistent reduction of erastin-mediated
AKR1C1 ÷ 3 upregulation (Fig. 4d). Finally, to check
whether NRF2 activation under ferroptotic condition
might also be responsible for the ER stress-independent
CHAC1 early upregulation, the mRNA levels of CHAC1
were evaluated in the same experimental conditions, in
both sensitive and resistant cell lines. Data reported in
Fig. 3 Lipid peroxides generation by 12/15-LOX and degradation by AKR1C1÷3. A2058 (a), A375 (b) and CHL-1 (c) were untreated “C”, or
treated or with 20 μM Baicalein “B”, 10 μM MPA “M”, 10 μM Erastin “E”, Erastin plus MPA “E+M”, Erastin plus Baicalein (A2058) “E+ B” or Erastin plus
MPA plus Baicalein (A375 and CHL-1) “E+M+ B”. Lipid peroxides generation was evaluated at 16 h (A2058) or 24 h (A375 and CHL-1) (left panels),
while cell viability was evaluated at 24 h (A2058) or 48 h (A375 and CHL-1) (right panels). Representative flow cytometry profiles of lipid ROS staining
are also shown. (Histograms represent mean ± s.d.; n= 3; *p < 0,05).
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Fig. 4e and Supplementary S9C indicate that NRF2 inhi-
bition resulted in complete abrogation of ERA-stimulated
CHAC1 upregulation. These data are also confirmed by
results showing enhanced basal expression of both
CHAC1 (3,02) and AKR1C1 (1,75) in CHL-1 cells over-
expressing NRF2, compared to control cells (GFP; Suppl.
S10).
Melanoma cell lines differentiation and ferroptosis
resistance
During the preparation of this manuscript, Graeber’s
research group published data showing that primary
tumor-derived melanoma cells are characterized by a wide
‘differentiation status’, sharing a gene expression signature
based on a panel of nine genes43. Interestingly, they
identified a correlation between cancer cell differentiation
and ferroptotic cell death susceptibility. Since our
experimental model is based on metastasis-derived mel-
anoma cells, with no specific and available indication
about their differentiation status, we decided to evaluate
and compare the gene expression level of Graeber’s
identified ‘differentiation genes panel’ in our panel of cell
lines and verify a potential correlation with sensitivity to
erastin-induced ferroptosis. To this aim, total mRNA was
extracted from CHL-1, SK-Mel 5, A375, A2058 and
C8161 cells and the mRNA levels of MITF, SOX9,
SOX10, SMAD3, CTNNB1, AXL, EGFR, and ERBB343
were evaluated by qRT-PCR. Our comparative analysis
was performed using the most resistant CHL-1 cell line as
reference (which expression was set to 1, in each analysis;
Fig. 5a). Surprisingly, results indicate a differential and
extremely heterogeneous expression of indicated markers
in our cell lines, with a no clear ‘differentiation signature’
and/or correlation with ferroptosis susceptibility (Fig. 5b).
We therefore performed a PCA (Principal Component
Assay) and a Hierarchical Clustering analysis of our data
set. Both analyses reported in Fig. 5c, d show that the mild
(as shown in Fig. 5a) resistant SK-Mel 5 are close related
to resistant A375, thus being part of the same group, while
the most resistant CHL-1 are surprisingly close related to
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the sensitive A2058, thus being part of a second group.
Moreover, the most sensitive C8161 is approximately
equally distant from both previous groups, although more
related to the A375/SK-Mel 5 than the CHL-1/A2058
group (Fig. 5c, d).
We can conclude that Graeber’s ‘differentiation sig-
nature’ and correlation with cell’s sensitivity to ferroptosis
cannot be applied to our panel of metastasis-derived
melanoma cells. This can potentially be explained, at least
in part, by the heterogeneous source of our cells, such as
lymph nodes for A2058 and SK-Mel 5, abdominal wall
metastatic site for C8161, skin for A375, and pleural
effusion metastatic site for CHL-144.
However, during this screening we observed a differ-
ential basal expression of another gene implicated in the
ferroptotic process, SLC7A11 (part of the XC
- system
multiprotein complex; Fig. 5e) that correlates with our cell
line sensitivity to ferroptosis execution (R2= 0,7874;
Fig. 5f). We also measured the basal expression of another
gene previously proposed as ferroptosis sensitivity marker,
ACSL445, and confirmed that the expression of this factor
is preferentially enhanced also in ferroptosis sensitive
melanoma cells, compared to resistant ones (Suppl. S11).
However, the correlation with cell death seems to be less
accurate compared to SLC7A11 (R2= 0,7874 vs R2=
0.4962, referred to ACSL4).
Therefore, although future studies are required to better
define the meaning of this correlation at molecular level,
we can speculate SLC7A11 might represent a useful
marker to predict metastatic melanoma cells susceptibility
to ferroptosis execution, possibly coupled to ACSL4 gene
expression analysis (Suppl S12).
AKR1C1 ÷ 3 are expressed at low level in melanoma tumor
in vivo
The expression of AKR1C ÷ 3 was also evaluated in
primary melanoma tumor samples compared to normal
tissues, by using the GEPIA (Gene Expression Profiling
Interactive Analysis) free online platform, available at
http://gepia.cancer-pku.cn/index.html46. The analysis was
carried out on 461 tumor and 558 normal tissues samples.
Thus, the comparative analysis revealed that the three
enzymes are expressed in both tumor and normal tissue
but, interestingly, their level is statistically significant
lower in tumor compared to normal tissue samples
(Fig. 6a), while very low expression and not statistically
significant difference are observed analyzing the expres-
sion of the unrelated AKR1C4 member (Suppl. S13A).
Importantly, there is a clear correlation between the
expression of each of the three AKRs and the other two
members of the same family of enzymes (Fig. 6b; R= 0,71
in C1 vs C2; R= 0,46 in C1 vs C3; R= 0,45 in C2 vs C3),
while there is no correlation between each of the three
enzymes and the expression of the unrelated C4 (Suppl.
S13B; R= 0,098 in C1 vs C4; R= 0,078 in C2 vs C4; R=
0,091 in C3 vs C4). Moreover, no change was observed, in
any of the three AKRs, during the tumor stage progres-
sion (Suppl. S13C). Next, we also compared the overall
survival from patients characterize by low vs high
AKR1C1, AKR1C2, or AKR1C3. This analysis revealed
that there is no significative difference linked to low or
high AKR1C1 ÷ 3 expression (Fig. 6c). Due to our results
indicating a NRF2-dependt AKR gene expression regula-
tion under pro-ferroptotic drugs, we also evaluated the
expression of this TF in the same data set reported above.
This analysis indicates a slight reduced expression of
NRF2 in tumor compared to normal tissue samples
(Suppl. S13D) with no significant change during tumor
stage progression (Suppl. S13E). Finally, our analysis also
shows no link between overall patient’s survival rates and
low/high NRF2 expression (Suppl. S13F). Finally, since
12/15-LOX are implicated in lipid peroxides generation
under ferroptosis execution in melanoma cell lines, we
also evaluated the expression of these factors in both
tumor and normal tissue samples. Results indicate a
reduced expression of both enzymes in tumor samples
compared to normal tissues (Suppl. S13G) with no change
during tumor stage progression (Suppl. S13H).
Discussion
Human malignancies are currently one of the world’s
worst problems that both clinicians and researchers face
daily and although effective therapies have progressed thus
sustaining patient’s survival in some of them, others are
unfortunately still far from a definitive cure. Human skin
melanoma is one of the latter, with an increasing incidence
rate over years, high aggressiveness, still unfavorable clinical
outcome, and refractory to any anti-tumor therapy devel-
oped till now. Therefore, there’s an urgent need of effective
therapeutic strategies to treat this tumor. The deep dis-
section of molecular mechanisms responsible for melano-
magenesis and tumor resistance to pro-death drugs will
help to define new targets and more effective therapeutic
strategies. Here we explored an alternative strategy to kill
melanoma cells based on the induction of the unconven-
tional cell death pathway named ferroptosis. Interestingly
we found that this non-apoptotic signaling pathway is effi-
ciently induced in all cells of our panel of commercially
available melanoma cell lines, as evidenced by the fast,
consistent and sustained upregulation of the early marker
CHAC1. It has been previously reported a potential link
existing between the apoptotic and ferroptotic cell death
pathways relaying on the activation of ER stress, also pos-
sibly responsible for CHAC1 gene expression modulation
under ferroptotic conditions47. However, we found that the
UPR signaling pathway is not significantly induced upon
ferroptosis induction in our panel of melanoma cell lines,
thus indicating the existence of an ER stress-independent
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Fig. 6 Gene expression profiling analysis. a A comparative expression analysis of AKR1C1, AKR1C2 and AKR1C3 was evaluated SKCM and normal
tissue data sets. b A correlative analysis between AKR1C1 vs AKR1C2, AKR1C1 vs AKR1C3 and AKR1C2 vs AKR1C3 was performed in the SKCM data set.
c The overall survival was evaluated in both high and low expressing AKR1C1, AKR1C2 or AKR1C3 patients. The total number of samples analyzed was
indicated under each boxplot. d Graphic illustration showing the molecular mechanisms conferring resistance of metastatic melanoma cells to the
execution of ferroptosis, and potential therapeutic interventions to counteract and/or resensitize cancer cells to ferroptosis.
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upregulation of CHAC1 under ferroptotic conditions. In
fact, the inhibition of the PERK/ATF4/CHOP pathways,
known to regulate CHAC1 expression27,28, did not result in
gene expression abrogation of this marker upon ferroptosis
induction. These results are of particular interest since
dysregulated UPR is frequently involved in cancer cell
development and resistance to therapy48, and has a pivotal
role in oncogenic BRAF melanoma cells resistance to pro-
apoptotic stimuli13.
Although competent in inducing the early stages of
ferroptosis, most of our cell lines (5 out of 7) were unable
to die though ferroptosis, independently from oncogenic
BRAF expression and kinase activity inhibition (through
short-term incubation with vemurafenib; 24 h), indicating
a downstream block of the pathway. In fact, resistant cells
showed low production of lipid peroxides, the key execu-
tioner of this cell death program, compared to sensitive
cells, and only resistant cells were characterized by fast,
consistent and sustained expression of AKRs (AKR1C1 ÷ 3),
potentially responsible for lipid peroxides reduction and,
thus, cell death inhibition. The inhibition of AKRs enzy-
matic activity or gene expression confirmed the latter
hypothesis. Indeed, the AKRs pan inhibitor MPA or gene
silencing (through shRNA) were able to restore the pro-
duction of high levels of lipid peroxides resulting in cell
death execution of all resistant cells. Therefore, we found
new potential target to revert ferroptosis resistance, at least
in melanoma cells. Further studies are, however, required to
verify whether this resistance strategy is peculiar of mela-
noma cells or might represent a general cancer cell strategy
to escape a pro-ferroptotic treatment. Interestingly, we also
observed a heterogeneous extent of AKRs upregulation
upon ferroptosis induction among resistant cells, with a
‘bona fide’ inverse correlation with their basal expression.
The key role of AKRs in lipid peroxide detoxification and
ferroptosis resistance was finally evidenced in sensitive cells
in which the ectopic expression of one of the AKRs resulted
in the conversion of sensitive into resistant cells and,
importantly, the inhibition of its enzymatic activity com-
pletely reverted their phenotype. Interestingly, the analysis
of AKRs expression performed by the Gene Expression
Profiling Interactive Analysis (GEPIA) revealed that the
three enzymes (AKR1C1 ÷ 3) are expressed at low level in
tumor samples compared to normal tissue with no corre-
lation between gene expression and patient’s survival rates.
Further in vivo studies are therefore required to verify the
enhanced expression of AKRs in ferroptotic resistant
patients.
Although lipid peroxide generation was originally linked
to intracellular iron accumulation, through the Fenton’s
reaction32,49, it now generally accepted that these key
ferroptotic executioner can also be generated by lipox-
ygenases. This is also the case of melanoma cells since the
inhibition of 12/15-LOX but not 5-LOX resulted in both
complete abrogation of lipid peroxides production and
cell death execution under ferroptotic treatment in both
sensitive and MPA-treated resistant cells.
Finally, our current study indicates that NRF2 is actively
involved in melanoma cell resistance to ferroptotic cell
death since its expression, together with its downstream
target HO1, increased at both mRNA and protein levels in
resistant cells, upon treatment. Importantly, the phar-
macologic inhibition of NRF2 activity inhibited the
ferroptosis-induced upregulation of AKRs. Moreover, the
inhibition of NRF2 activity also resulted in complete
abrogation of CHAC1 early upregulation upon ferroptosis
induction, thus delineating a new rote though which
CHAC1 expression is modulated during ferroptosis
induction/execution (Fig. 6d).
During the preparation of this manuscript, Graeber and
colleagues published data showing a correlation between
primary tumor-derived melanoma cell’s differentiation and
ferroptosis resistance, identifying a panel of genes which
expression well recapitulated the differentiation status of
these cells43. However, this ‘differentiation signature’
seems not to be applicable to metastasis-derived mela-
noma cells possibly because the latter are not derived
(most of them) by primary tumors but from secondary
metastatic sites. Consequently, since the metastatic phe-
notype is associated with an epithelial–mesenchymal
transition (EMT), this implies a cells reprogramming thus
resulting in a new repertoire of expressed genes, to sup-
port specific adhesive, invasive, and migratory properties50.
However, although Graeber’s ‘differentiation signature’
failed in defying the differentiation status of our cells and
the consequent relation with ferroptosis resistance, we
found a positive correlation between the basal expression of
SLC7A11 (a member of the System XC
-) and cell’s resis-
tance to ferroptosis execution. Therefore, although further
studies are required, and an extended panel of metastatic
melanoma cell lines should be screened to verify this rela-
tion, it is possible to speculate that this factor might
represent a new potential marker to predict metastatic
melanoma sensitivity to ferroptotic cell death, possibly
coupled to other potential markers such as ACSL4. Inter-
estingly, very recently Zhang and colleagues showed a link
between the tumor suppressor BRCA1-associated protein 1
(BAP1) mutational status and SLC7A11 expression in uveal
melanoma51. However, data on BAP1 mutational status in
skin melanoma are still missing. Our work thus motivates
further studies to elucidate the potential link between BAP1
and SLC7A11 in human skin melanoma.
To the best of our knowledge ferroptosis resistance has
not previously been associated with AKRs upregulation/
activation. Our study thus identifies a new potential
therapeutic strategy to efficiently kill melanoma cells
based on pro-ferroptosis drugs coupled to AKR1C1 ÷ 3
inhibitors (Fig. 6d).
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Methods and materials
Cell culture and treatments
Human melanoma cell lines used were: MeWo, A2058,
SK-Mel 5, SK-Mel 24, C8161, CHL-1, and A375. Cell
identity was confirmed by short tandem repeat analysis
(STR) and the DSMZ Online STR Analysis52, and
Mycoplasma testing was routinely performed each month
by using the Venor®GeM Classic (Minerva-BiolAbs;
Berlin, GE).
Cell lines (BRAFWT: CHL-1, SK-Mel 24 and MeWo;
BRAFV600E: A375, A2058 and SK Mel-5; BRAFG464E:
C8161) were cultured in DMEM (Sigma-Aldrich; Milan,
IT), supplemented with 10% foetal bovine serum (Sigma-
Aldrich), 2mM L-glutamine (Sigma-Aldrich), 1% peni-
cillin/streptomycin solution (Sigma-Aldrich) at 37 °C
under 5% CO2. All reagents were purchased from Sigma-
Aldrich if not differently indicated. Cells were treated with
Thapsigargin 10 μg/ml, Erastin 10 μM, Brusatol 50 nM
(Cayman Chemicals; Ann Arbor, MI, US); Medrox-
yprogesterone 10 μM, Baicalein 20 μM, MG132 10μM,
H2O2 500 μM; Deferoxamine 100μM (Cayman Chemi-
cals); Zileuton 10 μM (Cayman Chemicals); Ferrostatin-1
10 μM; Vemurafenib 10 μM; 2-Mercaptoethanol 100μM;
RLS3 2μM (Sigma-Aldrich).
Lentiviral generation and infection
Co-transfection of lentiviral vectors (shRNA-pLKOs
AKR1C1, shRNA-pLKOs AKR1C2, shRNA-pLKO
AKR1C3; Sigma-Aldrich) (10 μg), vesicular stomatitis virus
G protein expression plasmid (2,5 μg) and psPAX2 plasmid
(carrying gag, pol and rev genes) was performed using 293T
packaging cell line, by a calcium phosphate protocol.
Supernatants with lentiviral particles were harvested 48 h
later and supplemented with 4 μg/ml of polybrene. These
supernatants were used to infect target cells30.
RNA interference
hATF4 and non-targeting scramble (siCTRL, used as
negative control) siRNA oligoribonucleotides were
obtained from Invitrogen (Carlsbad, CA, US). Silencing
was performed as previously reported. Briefly, 25 × 104
cells/well were seeded in six-well plates and transfected
with siRNA (100 pmol) by means of RNAi Max (Invitro-
gen) as recommended by the supplier. 24 h later, cells were
trypsinized, plated at 30 × 104 cells/well in six-well plates
and treated with the indicated agents. Quantitative RT-
PCR (qRT-PCR) analysis was used to assess RNA down-
regulation after 48 h from transfection, as described below.
Cell transfection
AKR1C3 encoding vector (RC200210–AKR1C3
(NM_003739) Human Tagged ORF Clone) was purchased
from OriGene (Rockville, MD, US). A total of 25 × 104
cells/well were transfected with 1 µg of total DNA in six-
well plates by using Lipofectamine LTX (Invitrogen) for
8 h, as recommended by the supplier. At 24 h after
transfection, cells were trypsinized, plated at 30 × 104
cells/well in six-well plates and treated as indicated.
Western blotting
Protein extraction was performed by using Cell Lytic
buffer (Sigma-Aldrich) supplemented with a protease
inhibitors cocktail (Sigma-Aldrich) plus phosphatases
inhibitors (Na3VO4 1mM; NaF 10mM) and resolved by
electrophoresis through NuPAGE Bis-Tris gel (Invitro-
gen) and electroblotted onto nitrocellulose (Protran,
Sigma-Aldrich) membrane. Blots were incubated with
indicated primary antibodies in 5% non-fat dry milk in
PBS plus 0.1% Tween20 overnight at 4 °C. Primary anti-
bodies were: anti-PERK (1:500; Cell Signaling; Danvers,
MA, US), anti-ERK1/2 (1:500; Cell Signaling), anti-ERK1/
2 (1:500; Cell Signaling), anti-Nrf2 (1:500; Genetex; Alton
Pkwy Irvine, CA, US), anti-Herp (1:500; Sigma-Aldrich),
anti-AKR1C1 (1:500; NOVUS), anti-AKR1C2 (1:500,
Merck), anti-AKR1C3 (1:500; Cell Signaling), anti-Tubu-
lin-α (1:5000; Santa Cruz Biotechnology; Santa Cruz, CA,
US). Detection was achieved using horseradish
peroxidase-conjugate secondary antibody (1:5000; Jackson
ImmunoResearch; Cambridge, UK) and visualized with
ECL plus (Amersham Biosciences; Amersham, UK).
Images were acquired by using a ChemiDoc™ Touch
Imaging System (Bio-Rad; Berkeley, CA, US) and analyzed
by Image Lab software (Bio-Rad).
Quantitative RT-polymerase chain reaction
Trizol reagent (Invitrogen) was used to extract total
RNA as indicated by the supplier, and the AMV Reverse
Transcriptase kit (Promega; Madison, WI, US) was used
to produce cDNA following the manufacturer’s recom-
mendations. Quantitative PCR reactions were performed
by using the Rotor-Gene 6000 (Corbett Research Ltd;
Cambridge, UK) thermocycler. Supplementary Table S1
shows the primer pair sequences for all amplicons,
designed by using the online IDT PrimerQuest Tool
software (IDT; https://eu.idtdna.com/Primerquest/Home/
Index). L34 mRNA level was used as an internal control
and results were expressed as previously described.
Cell viability
Fluorescein diacetate (FDA)/7AAD staining was used to
identify and measure the percentage of live/dead cells.
Briefly, cells were incubated (10 min) with PBS containing
FDA (7 pg/ml) and 7AAD (50 ng/ml) and 10’000 events
were acquired by flow cytometry. The percentage of FDA
positive and 7AAD negative cells was measured and
indicated as ‘Cell Viability (%)’.
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Lipid peroxides evaluation
Briefly, 1.5 × 105 cells were treatment as indicated and
cells harvested at indicate time points. Then, cells were
pelleted, washed by PBS, resuspended in BODIPY C11
(2 μM in PBS; Invitrogen), incubated at 37 °C for 15 min
in the dark, and 10.000 events were acquired by using a
FACS Calibur cytometer (Becton-Dickinson; Franklin
Lakes, NJ, US). Data analysis was performed using the
Flowing Software.
PCA and hierarchical cluster analysis
The original expression data for the panel composed by
the eight genes across the five cell lines reported in
Supplementary Table S2 were subject to two different
analysis: a PCA (Principal Component Analysis) and a
hierarchical clustering (Euclidean clustering distance,
complete linkage). Data were log2 transformed and scaled
with respect to the gene median value. A pseudo-count of
0.01 was added to all samples. All the computations were
performed in the R statistical environment (https://www.
r-project.org/).
Gene expression profiling interactive analysis (GEPIA)
The analysis was performed by using the free online web
platform at http://gepia.cancer-pku.cn/index.html, which
details are available at http://gepia.cancer-pku.cn/help.
html and46. Briefly, the expression of each indicated gene
was evaluated in the skin melanoma, SKCM, data set
matched with ‘TCGA normal and GTEx data’ set (normal
tissue), with a |Log2FC| Cutoff of 1, a p-value Cutoff of
0.01, and results showed using a log2(TPM+ 1) log scale.
The overall survival curves were generated by using the
following parameters: Group Cutoff=Median, with
Cutoff-High (%)= 50 and Cutoff-Low (%)= 50; Hazards
Ratio (HR)= Yes. Gene correlation analysis was per-
formed in the SKCM data set by using the Pearson Cor-
relation Coefficient, with a non-log scale for calculation
and a log-scale axis for visualization.
Statistical analysis
All experiments were performed at least triplicate. Data
showed in this paper are representative of 3 independent
experiments carried out in triplicate; western blotting
images are from a representative experiment carried out
in triplicate. Statistical analysis was performed using
GraphPad Prism 6 and Student’s t test was used to
determine statistical significance. A p-value of equal to or
less than 0.05 was considered significant.
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